Bringing PET imaging into focus

Thunder Bay and Toronto, Ontario, Canada – Radialis today announced that it has secured financing to further grow its high-definition organ-targeted PET business through investments led by the Axion Fund of Archangel Networks.

“We were attracted to the strength of the proprietary Radialis technology and the opportunity for organ-targeted PET to transform nuclear imaging, particularly with regards to targeted early detection of a wide spectrum of conditions,” said Aaron Rezaei, of Archangel Networks. “Genetics are increasingly able to identify individuals who are at high risk for life-threatening illnesses and treatments are most effective when they are administered early in disease progression. Low-dose PET imaging may be the key to identifying the right patients for the right treatment at the right time.”

“We welcome the support from Archangel Networks for our work,” said Michael Waterston, President and CEO of Radialis. “Archangel brings not only capital, but also expertise in scaling sophisticated medical technology manufacturing and will ensure that we are well-prepared for our commercial launch.”

About Radialis

Radialis delivers best-in-class organ-targeted positron emission tomography (PET) medical imaging systems. Radialis’ facility for advanced manufacturing of medical devices is in Thunder Bay, Ontario.

Forward-Looking Statement

Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Although we believe that any forward-looking statements contained in this press release are reasonable, there can be no assurance that any such forward-looking statements will prove to be accurate. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements.

Media Contact:
Michael Waterston
info@radialismedical.com
1-800-601-3177 ext. 2

‍